Ian Spatz is a senior adviser in the national health care practice of Manatt, Phelps and Phillips, LLP, and Manatt Health. He counsels clients on health reform efforts and issues affecting health care providers and insurers, pharmaceutical companies, the consuming public, and US health care initiatives. His work areas include national health care policies and programs; pharmaceutical pricing, including as it relates to Medicare and Medicaid; intellectual property protection; and policies related to the Food and Drug Administration’s regulation of the research, approval, manufacturing, and marketing of medicines. Spatz is also the founder and principal of the policy consulting firm Rock Creek Policy Group. Prior to joining Manatt, Spatz served 15 years in increasingly responsible positions at Merck and Company. As Merck’s vice president for global health policy, he directed US public policy and related public affairs activities and represented the company before Congress, the White House, and the media. Before joining Merck, Spatz served as legislative director for Sen. Frank Lautenberg (D-NJ). In that role, he directed the senator’s legislative staff in developing and implementing legislative strategies, proposal drafting, and floor action, including coordinating the passage of appropriations bills. Spatz is a member of the faculty of the University of Southern California’s Price School of Public Policy where he teaches courses in health economics and health law.


Recent Posts by Ian Spatz

California Takes On Drug Pricing: Real Progress Or Illusion?

California SB-17 has already succeeded in serving as an outlet for frustration with high and rising prescription drug prices. It has sent a message to the drug industry that it cannot stop all the legislation it opposes.